Literature DB >> 31922900

Subacute TGFβ Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway.

Elizabeth L Kramer1,2, Satish K Madala1,2, Kristin M Hudock3,4, Cynthia Davidson2, John P Clancy1,2.   

Abstract

Cystic fibrosis (CF) is a lethal genetic disease characterized by progressive lung damage and airway obstruction. The majority of patients demonstrate airway hyperresponsiveness (AHR), which is associated with more rapid lung function decline. Recent studies in the neonatal CF pig demonstrated airway smooth muscle (ASM) dysfunction. These findings, combined with observed CF transmembrane conductance regulator (CFTR) expression in ASM, suggest that a fundamental defect in ASM function contributes to lung function decline in CF. One established driver of AHR and ASM dysfunction is transforming growth factor (TGF) β1, a genetic modifier of CF lung disease. Prior studies demonstrated that TGFβ exposure in CF mice drives features of CF lung disease, including goblet cell hyperplasia and abnormal lung mechanics. CF mice displayed aberrant responses to pulmonary TGFβ, with elevated PI3K signaling and greater increases in lung resistance compared with controls. Here, we show that TGFβ drives abnormalities in CF ASM structure and function through PI3K signaling that is enhanced in CFTR-deficient lungs. CF and non-CF mice were exposed intratracheally to an adenoviral vector containing the TGFβ1 cDNA, empty vector, or PBS only. We assessed methacholine-induced AHR, bronchodilator response, and ASM area in control and CF mice. Notably, CF mice demonstrated enhanced AHR and bronchodilator response with greater ASM area increases compared with non-CF mice. Furthermore, therapeutic inhibition of PI3K signaling mitigated the TGFβ-induced AHR and goblet cell hyperplasia in CF mice. These results highlight a latent AHR phenotype in CFTR deficiency that is enhanced through TGFβ-induced PI3K signaling.

Entities:  

Keywords:  CFTR; airway hyperresponsiveness; airway smooth muscle; cystic fibrosis; transforming growth factor β

Mesh:

Substances:

Year:  2020        PMID: 31922900      PMCID: PMC7193791          DOI: 10.1165/rcmb.2019-0158OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  46 in total

1.  Convergence of signaling pathways on the activation of ERK in B cells.

Authors:  Anand Jacob; Damon Cooney; Madhura Pradhan; K Mark Coggeshall
Journal:  J Biol Chem       Date:  2002-04-25       Impact factor: 5.157

2.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

Review 3.  TGFβ as a therapeutic target in cystic fibrosis.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Ther Targets       Date:  2017-12-13       Impact factor: 6.902

4.  CF airway smooth muscle transcriptome reveals a role for PYK2.

Authors:  Daniel P Cook; Ryan J Adam; Keyan Zarei; Benjamin Deonovic; Mallory R Stroik; Nicholas D Gansemer; David K Meyerholz; Kin Fai Au; David A Stoltz
Journal:  JCI Insight       Date:  2017-09-07

5.  Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities.

Authors:  Ryan J Adam; Katherine B Hisert; Jonathan D Dodd; Brenda Grogan; Janice L Launspach; Janel K Barnes; Charles G Gallagher; Jered P Sieren; Thomas J Gross; Anthony J Fischer; Joseph E Cavanaugh; Eric A Hoffman; Pradeep K Singh; Michael J Welsh; Edward F McKone; David A Stoltz
Journal:  JCI Insight       Date:  2016-04-07

6.  Heritability of lung disease severity in cystic fibrosis.

Authors:  Lori L Vanscoy; Scott M Blackman; Joseph M Collaco; Amanda Bowers; Teresa Lai; Kathleen Naughton; Marilyn Algire; Rita McWilliams; Suzanne Beck; Julie Hoover-Fong; Ada Hamosh; Dave Cutler; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2007-03-01       Impact factor: 21.405

7.  Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis.

Authors:  William T Harris; Marianne S Muhlebach; Robert A Oster; Michael R Knowles; Terry L Noah
Journal:  Pediatr Pulmonol       Date:  2009-11

8.  Inhibition of allergen-induced airway remodeling in Smad 3-deficient mice.

Authors:  Annie V Le; Jae Youn Cho; Marina Miller; Shauna McElwain; Kirsti Golgotiu; David H Broide
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis.

Authors:  Chun Geun Lee; Soo Jung Cho; Min Jong Kang; Svetlana P Chapoval; Patty J Lee; Paul W Noble; Teshome Yehualaeshet; Binfeng Lu; Richard A Flavell; Jeffrey Milbrandt; Robert J Homer; Jack A Elias
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

10.  Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.

Authors:  R Reilly; M S Mroz; E Dempsey; K Wynne; S J Keely; E F McKone; C Hiebel; C Behl; J A Coppinger
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

View more
  2 in total

1.  Update in Pediatrics 2020.

Authors:  Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson
Journal:  Am J Respir Crit Care Med       Date:  2021-08-01       Impact factor: 30.528

2.  Is PI3K a Villain in Cystic Fibrosis?

Authors:  Viswanathan Natarajan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.